Understanding Insurance Coverage & Cost-Share Assistance with Marissa Shackleton

April 29, 2020

What Infusion Operators Should Know about Medically Integrated Dispensing

November 17, 2026

NICA Comments on Proposed HCPCS Coding Changes for Immune Globulin Products

June 2, 2026

Regulatory Comment

In June 2026, NICA submitted comments to the Centers for Medicare & Medicaid Services (CMS) expressing concerns about proposed Healthcare Common Procedure Coding System (HCPCS) changes for immune globulin products. NICA warned that changes to billing codes and units could create reimbursement challenges, increase administrative burdens, and disrupt existing prior authorizations. NICA urged CMS to delay or withdraw the proposal until adequate provider and payer readiness could be ensured.


June 2, 2026

Mehmet Oz, MD, MBA Administrator Centers for Medicare and Medicaid Services 200 Independence Avenue, SW Washington, DC 20201   

 Re: HCPCS Level II Public Meeting – Proposed HCPCS Coding Changes for Immune Globulin Products

Dear Administrator Oz:

The National Infusion Center Association (NICA) appreciates the opportunity to provide comments regarding the proposed HCPCS coding changes for immune globulin products. NICA is a nonprofit organization formed to support non-hospital, community-based infusion centers caring for patients in need of provider-administered medications. To improve access to medical benefit drugs that treat complex, rare, and chronic diseases, we work to ensure that patients can access these drugs in safe, more efficient, and cost-effective alternatives to hospital care settings. NICA supports policies that improve drug affordability for beneficiaries, increase price transparency, reduce disparities in safety across care settings, and foster patient access to the highest-quality, lowest-cost setting.

NICA writes to raise concerns regarding the proposed changes to HCPCS codes and billing units for certain immune globulin products. While NICA understands the importance of accurate coding and billing structures, CMS has not provided a sufficiently clear rationale for why these changes are necessary or how the anticipated benefits outweigh the potential disruption to providers, payers, and patients. Given the significant operational implications associated with implementing new HCPCS codes and billing units, stakeholders need a more robust explanation of the policy objectives, expected outcomes, and implementation considerations underlying the proposal. Absent that information, NICA is concerned that the proposed changes could create significant operational, billing, inventory, prior authorization, and patient access challenges for non-hospital, community-based infusion centers.

Immune globulin products are an important therapeutic class for many infusion providers and the patients they serve. Patients receiving these therapies often require long-term, recurring treatment for complex and chronic conditions. For that reason, even changes that may appear technical or administrative can have meaningful consequences if payer systems, provider workflows, authorizations, contracts, billing platforms, and inventory systems are not aligned and ready before implementation.

Operational and Billing Concerns for Non-Hospital Infusion Centers

NICA members have expressed concern that the proposed changes will create substantial operational complexity for community-based infusion providers. Immune globulin therapies represent a significant portion of business for many non-hospital infusion centers, and changes to HCPCS codes and billing units affect billing, inventory management, payer contracting, staff workflows, and claims processes.

These areas are highly interconnected. Infusion providers rely on accurate alignment between product ordering, inventory tracking, dose preparation, clinical documentation, HCPCS coding, billing units, prior authorization requirements, and claims submission. If these systems are not updated consistently and simultaneously, providers may be required to manage conflicting billing rules and payer requirements for the same products.

This concern is particularly acute because providers already navigate variation in how payers process drug claims, including differences between gram-based workflows, HCPCS unit-based billing, and payer-specific coverage and documentation requirements. Introducing new HCPCS codes and billing units without uniform payer adoption will increase the risk of billing errors, underpayments, denials, delayed reimbursement, and administrative burden.

Payer Readiness and Commercial Payer Alignment

NICA is especially concerned that Medicare implementation may not align with commercial payer readiness. Community-based infusion centers serve patients across multiple payer types, and commercial payers may not update their systems, fee schedules, contracts, prior authorization criteria, and claims processing logic on the same timeline.

If some payers adopt the new codes and billing units while others continue using existing requirements, providers will be forced to operate under overlapping and inconsistent billing frameworks. This would increase the likelihood of payment errors, claims rework, denials, and delayed reimbursement. It also creates confusion for staff responsible for verifying benefits, obtaining authorizations, documenting treatment, managing inventory, and submitting claims.

NICA members have also raised concerns that payer contracts may need to be updated to reflect new codes and billing units. If payer contracts and claims systems are not updated in a timely and consistent manner, providers will face avoidable reimbursement delays or underpayments for medically necessary therapies already furnished to patients.

Prior Authorization and Continuity of Therapy

NICA is concerned that changes to HCPCS codes and billing units will disrupt existing prior authorizations for patients who are already receiving immune globulin therapy. Many patients remain on these products long-term, and a change in codes or billing units could require that authorizations be updated or resubmitted mid-treatment.

This could be particularly disruptive if payers do not implement clear crosswalk logic between current and new codes. If payer systems are not prepared to recognize the relationship between existing authorizations and new billing codes, patients could experience treatment delays while providers seek clarification, correct denials, or resubmit authorization requests.

For patients receiving ongoing immune globulin therapy, continuity matters. These are not one-time administrative transactions; they are recurring therapies that often require careful scheduling, benefit verification, drug procurement, and clinical coordination. Any interruption in authorization or reimbursement processes creates downstream access issues for patients and providers.

Patient Access Implications

Although many of the concerns described above are operational, they ultimately affect patients. Administrative disruption can delay treatment, create uncertainty around coverage, and force providers to spend additional time resolving payer issues rather than coordinating care.

Non-hospital infusion centers play an important role in helping patients access complex provider-administered therapies in safe, community-based settings. If coding changes create avoidable reimbursement delays, inventory management problems, payer confusion, or prior authorization disruptions, many providers will face increased difficulty maintaining timely access to immune globulin therapies.

NICA urges CMS to consider these patient access implications carefully. A coding change that is not fully coordinated across payers and provider systems will create real-world barriers for patients who depend on consistent access to treatment.

Recommendations

NICA recommends that CMS pause or withdraw the proposed changes unless and until CMS can ensure adequate payer, provider, and system readiness. At minimum, if CMS proceeds, NICA urges CMS to adopt the following safeguards:

  • Delay implementation to allow sufficient time for stakeholder feedback, payer system updates, provider preparation, contract revisions, billing platform updates, inventory system changes, and staff training.
  • Provide an additional stakeholder engagement opportunity before finalizing or implementing these changes. Non-hospital infusion centers, payers, billing vendors, claims processors and clearinghouses, practice management system and electronic health record (EHR) vendors, manufacturers, and patient stakeholders should have a meaningful opportunity to identify operational risks and recommend practical implementation solutions.
  • Establish a transition policy requiring Medicare and other payers subject to CMS oversight to honor existing prior authorizations. Payers should use automatic crosswalk logic so that patients already approved for therapy do not experience avoidable delays or disruptions solely because a billing code or unit descriptor has changed.
  • Publish clear crosswalk guidance and unit-conversion tools well in advance of implementation. This guidance should be practical and operationally useful for providers, payers, billing vendors, and other stakeholders.
  • Ensure payer readiness before implementation and avoid proceeding on a timeline that leaves providers managing conflicting payer rules, outdated payer systems, or incomplete contract and claims processing updates.
  • Consider whether standardization across affected immune globulin products would reduce confusion and administrative burden if changes are ultimately implemented. A fragmented approach to billing units may increase complexity and error risk.

Conclusion

NICA appreciates CMS’ efforts to maintain accurate HCPCS coding and billing structures. However, NICA is concerned that the proposed changes to immune globulin coding and billing units will create significant operational, reimbursement, inventory, prior authorization, and patient access challenges for non-hospital, community-based infusion centers.

NICA urges CMS to pause or withdraw the proposal unless payer and system readiness can be assured. If CMS proceeds, the agency should delay implementation, provide additional stakeholder engagement, require a transition period, protect existing prior authorizations, publish clear crosswalk and unit-conversion guidance, and ensure payers are prepared before any changes take effect.

***

Thank you for the opportunity to comment on this important issue. We would welcome the opportunity to connect with you and provide any additional information regarding our concerns. Please do not hesitate to contact me, should you have any questions or wish to further discuss this issue: [email protected]

Sincerely,

Brian Nyquist, MPH Chief Executive Officer

National Infusion Center Association

Related Posts

August 4, 2026

NICA Comments on CMS Proposed Rule Regarding the Medicare Drug Price Negotiation Program for IPAY 2029

In August 2026, NICA submitted comments to the Centers for Medicare & Medicaid Services (CMS) on proposed changes to the Medicare Drug Price Negotiation Program. NICA […]
July 15, 2026

NICA Response to CMS’ Request for Information on the Essential Health Benefits Framework

In July 2026, NICA submitted comments on the Centers for Medicare & Medicaid Services’ (CMS) review of the Essential Health Benefits (EHB) framework. NICA highlighted concerns […]
March 13, 2026

NICA Comments on CMS’ Proposed 2027 Notice of Benefit and Payment Parameters

In March 2026, NICA submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed 2027 Notice of Benefit and Payment Parameters (NBPP). […]
✕

Login

When you login, you will be directed to admin.infusioncenter.org. When you get there:

  • Enter the email address that was used to claim your center in the Infusion Center Locator or
  • If you are looking to add your infusion center (i.e. it does not already exist as an unclaimed location in the locator), enter the email you would like to be associated with the location.

You will receive an email with a link to click that will log you into the resources section of the locator, which includes your claimed and/or activated infusion center(s).

Please note: you will have to enter your email each time as we no longer have passwords for extra security. This login process is separate from the forum.

If you have questions about the email address associated with the location, how to add or claim a center, how to purchase a resource, etc., please email our Member Relations lead, Ashley Kana at [email protected].

✕

NICA